CN118076638A - 新型抗sirpa抗体 - Google Patents

新型抗sirpa抗体 Download PDF

Info

Publication number
CN118076638A
CN118076638A CN202280053002.XA CN202280053002A CN118076638A CN 118076638 A CN118076638 A CN 118076638A CN 202280053002 A CN202280053002 A CN 202280053002A CN 118076638 A CN118076638 A CN 118076638A
Authority
CN
China
Prior art keywords
seq
sequence
antibody
cancer
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280053002.XA
Other languages
English (en)
Chinese (zh)
Inventor
卢宏韬
牛晓峰
王奉莉
王春年
赵金凤
邢柔媚
王海莹
于景丰
李磊
吴志浩
高瑞
邱阳生
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kewang Shanghai Biomedical Technology Co ltd
Kewang Suzhou Biomedical Technology Co ltd
Original Assignee
Kewang Shanghai Biomedical Technology Co ltd
Kewang Suzhou Biomedical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kewang Shanghai Biomedical Technology Co ltd, Kewang Suzhou Biomedical Technology Co ltd filed Critical Kewang Shanghai Biomedical Technology Co ltd
Publication of CN118076638A publication Critical patent/CN118076638A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cell Biology (AREA)
CN202280053002.XA 2021-07-28 2022-07-28 新型抗sirpa抗体 Pending CN118076638A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/109041 2021-07-28
CN2021109041 2021-07-28
CNPCT/CN2022/104562 2022-07-08
CN2022104562 2022-07-08
PCT/US2022/074286 WO2023010100A1 (en) 2021-07-28 2022-07-28 Novel anti-sirpa antibodies

Publications (1)

Publication Number Publication Date
CN118076638A true CN118076638A (zh) 2024-05-24

Family

ID=85087323

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280053002.XA Pending CN118076638A (zh) 2021-07-28 2022-07-28 新型抗sirpa抗体

Country Status (9)

Country Link
US (1) US20250270315A1 (https=)
EP (1) EP4377358A4 (https=)
JP (1) JP2024531900A (https=)
KR (1) KR20240039006A (https=)
CN (1) CN118076638A (https=)
AU (1) AU2022317822A1 (https=)
CA (1) CA3227854A1 (https=)
TW (1) TW202313699A (https=)
WO (1) WO2023010100A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120569409A (zh) * 2023-01-18 2025-08-29 科望(苏州)生物医药科技有限公司 靶向sirpa和claudin 18.2的双特异性分子
EP4702053A1 (en) * 2023-04-27 2026-03-04 LaNova Medicines Limited Combination treatment targeting sirpa and claudin 18.2
WO2025140296A1 (zh) * 2023-12-26 2025-07-03 上海宏成药业有限公司 抗dll3抗体或其抗原结合片段及其用途
KR20250164033A (ko) * 2024-05-14 2025-11-24 주식회사 지놈앤컴퍼니 항-bcam 항체 및 이의 컨쥬게이트

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3334757A4 (en) * 2015-08-14 2019-04-03 Merck Sharp & Dohme Corp. ANTI-Tigit ANTIBODY
KR20250079073A (ko) * 2018-07-10 2025-06-04 고쿠리츠다이가쿠호진 고베다이가쿠 항 SIRPα 항체
WO2021032078A1 (en) * 2019-08-20 2021-02-25 Elpiscience (Suzhou) Biopharma, Ltd. Novel anti-sirpa antibodies
JP7437815B2 (ja) * 2019-12-24 2024-02-26 ラノバ メディシンズ リミテッド 抗ＳＩＲＰαモノクローナル抗体およびその使用

Also Published As

Publication number Publication date
CA3227854A1 (en) 2023-02-02
AU2022317822A1 (en) 2024-02-22
EP4377358A1 (en) 2024-06-05
US20250270315A1 (en) 2025-08-28
WO2023010100A1 (en) 2023-02-02
TW202313699A (zh) 2023-04-01
JP2024531900A (ja) 2024-09-03
KR20240039006A (ko) 2024-03-26
EP4377358A4 (en) 2025-12-17

Similar Documents

Publication Publication Date Title
AU2020286284B2 (en) Novel anti-CD39 antibodies
CN112867507B (zh) 新型抗sirpa抗体
CN107921122A (zh) 与cd38结合的抗体治疗剂
WO2018117237A1 (ja) 抗ｃｄ３抗体及び該抗体を含む分子
JP2024513239A (ja) Ｒｏｒ１に結合する抗原結合タンパク質
CN118076638A (zh) 新型抗sirpa抗体
WO2024131962A1 (zh) 新型抗gprc5d抗体
CN119278217A (zh) 新型抗gprc5d抗体、结合gprc5d和cd3的双特异性抗原结合分子以及其用途
CN116472350A (zh) 新型抗cldn18抗体
CN118055946A (zh) 新型多特异性分子
CN115698066A (zh) 抗cd47抗体及其用途
HK40106257A (zh) 新型抗sirpa抗体
US20240317880A1 (en) Epithelial Cadherin-Specific Antibodies
HK40045149A (en) Novel anti-sirpa antibodies
TW202542184A (zh) 與ｃｄ３及ｌｉｌｒｂ４結合之新穎抗體及其用途
CN120513257A (zh) 新颖多特异性抗体及其用途
CN116120461A (zh) 新型抗药抗体以及其用途
HK40041672A (en) Novel anti-cd39 antibodies
EA048967B1 (ru) Антитела к клаудину 18 и способы их применения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40106257

Country of ref document: HK